These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 30896929)

  • 21. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
    Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
    J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Al
    Palangka CRAP; Hanaoka H; Yamaguchi A; Murakami T; Tsushima Y
    Ann Nucl Med; 2019 Oct; 33(10):733-739. PubMed ID: 31297699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
    Jiang M; Ferdani R; Shokeen M; Anderson CJ
    Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
    Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
    J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1.
    Rosestedt M; Velikyan I; Rosenström U; Estrada S; Åberg O; Weis J; Westerlund C; Ingvast S; Korsgren O; Nordeman P; Eriksson O
    Nucl Med Biol; 2021 Feb; 93():54-62. PubMed ID: 33321470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
    Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
    Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
    Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
    Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
    Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET Imaging of VLA-4 in a New BRAF
    Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
    Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
    Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
    Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative preclinical evaluation of
    Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
    J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [
    Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
    Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single step 18F-labeling of dimeric cycloRGD for functional PET imaging of tumors in mice.
    Li Y; Liu Z; Lozada J; Wong MQ; Lin KS; Yapp D; Perrin DM
    Nucl Med Biol; 2013 Nov; 40(8):959-66. PubMed ID: 24090672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of [
    Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
    Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
    Ruivo E; Adhikari K; Elvas F; Fissers J; Vangestel C; Staelens S; Stroobants S; Van der Veken P; Wyffels L; Augustyns K
    Nucl Med Biol; 2019; 76-77():36-42. PubMed ID: 31707309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of structural alterations on the radiopharmacological profile of
    Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
    Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
    Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
    J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.
    Xu J; Yang J; Gonzalez R; Fisher DR; Miao Y
    Cancer Biother Radiopharm; 2019 Nov; 34(9):597-603. PubMed ID: 31644317
    [No Abstract]   [Full Text] [Related]  

  • 40. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
    J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.